White, Michael G.
Schulte, Jefree J.
Xue, Lai
Berger, Yaniv
Schuitevoerder, Darryl
Vining, Charles C.
Kindler, Hedy L.
Husain, Aliya
Turaga, Kiran K.
Eng, Oliver S.
Article History
Received: 7 August 2020
Revised: 5 October 2020
Accepted: 8 October 2020
First Online: 26 October 2020
Ethics approval and consent to participate
: This study was approved by the University of Chicago Institutional Review Board. Consent was waived as a retrospective review of patient charts under IRB19-0793.
: All informed consents were obtained. This report does not contain any individual person’s information.
: The data that support the findings of this work are available from the corresponding author upon request.
: H.L.K. reports personal fees from Aldeyra Therapeutics, personal fees and non-financial support from AstraZeneca, personal fees from Bayer, personal fees and non-financial support from Boehringer-Ingelheim, personal fees from Bristol Myers Squibb, personal fees from Kyowa, personal fees and non-financial support from Merck, personal fees and non-financial support from Paredox Therapeutics, personal fees from Inhibrx, personal fees from Deciphera, personal fees and non-financial support from Inventiva. The remaining authors have no competing interests to report.
: M.G.W. is supported through the National Institute of Health Kirschtein National Research Service (T32) Award. This work was supported using internal research fund through the University of Chicago, Department of Surgical Oncology.